Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, gives his perspective on the approval of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.

Oncology pharmacists are important to the oncology care team, as they can bring a unique perspective to treatment planning, according to Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC.

Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.

Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.

While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses what strategies are being used to treat patients with bladder cancer during the chemotherapy shortage.

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.

Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.

Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, offers a perspective on a clinical quandary published recently in the journal ONCOLOGY.

Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.

Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.